Answers are grounded in this paper and cite their sources.
Electronic cigarettes (e-cigarettes), also called vapes or Electronic Nicotine Delivery Systems (ENDS), were introduced as a less harmful alternative to combustible tobacco. Their wide range of flavours, discreet designs and aggressive marketing, however, have made them especially attractive to adolescents and young adults, raising concerns about nicotine addiction, respiratory and cardiovascular effects and exposure to toxic aerosol constituents. Governments have responded in very different ways: some treat e-cigarettes as consumer goods, others as tobacco products, medicines or medical devices, and a number of countries prohibit them altogether. This review examines the evolving regulatory landscape for e-cigarettes in the European Union, the United States, Australia, India and several other countries. It summarises the chemical constituents and health effects that motivate regulation, the working of the devices, the first marketing authorisation granted by the US Food and Drug Administration (FDA) as a case study, and the quality, safety, packaging, labelling, retail and advertising requirements imposed by each jurisdiction. Recent developments, including enforcement actions in 2024, the 2025 US Supreme Court ruling on flavoured products, Australia's pharmacy-only model and the UK ban on disposable vapes, are also discussed, together with nicotine replacement therapies as approved alternatives. The review highlights the absence of a unified global framework and the practical difficulty of enforcing prohibitions, and argues for a coordinated approach, similar to the WHO Framework Convention on Tobacco Control, that protects young people while preserving access to harm-reduction options for adult smokers.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: